A5046669922- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Tracheal and airway disorders
- Urological Disorders and Treatments
- Pulmonary Hypertension Research and Treatments
- Genital Health and Disease
- Metastasis and carcinoma case studies
- Vascular Anomalies and Treatments
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Urologic and reproductive health conditions
- Neuroendocrine Tumor Research Advances
Daiichi Sankyo (United States)
2024-2025
Shizuoka Red Cross Hospital
1997
Trastuzumab deruxtecan (T-DXd) showed statistically significant clinical improvement in patients with human epidermal growth factor receptor 2-positive (HER2
<p>Immune infiltration in tumors at baseline and association with response to T-DXd therapy. <b>A,</b> Tumoral CD8<sup>+</sup> cell densities, as determined using mIHC, responders nonresponders. <b>B, </b><i>CD8A</i> <i>CD8B</i> mRNA expression levels, RNA-seq, CPM, counts per million. <b>C,</b> Relationship between immune densities for cells expressing CD4, CD68, CD20, CD163, CD208, CD1a, mIHC IHC....
<p>Unsupervised hierarchical clustering analysis based on cell densities of evaluated immune cells at baseline. <b>A,</b> Heatmap depicting unsupervised results and characteristics the three observed groups. <b>B, </b><i>ERBB2</i> expression levels in groups obtained from clustering. <b>C,</b> Kaplan–Meier OS PFS curves 1, 2, 3 grouped by cells. CPM, counts per million; ECOG PS, Eastern Cooperative Oncology Group performance status; I/O,...
<p>Tumor-infiltrating immune cell densities at baseline and in response to T-DXd therapy responders nonresponders. <b>A,</b> Tumor-infiltrating CD8<sup>+</sup> T-cell densities, as determined using mIHC. <b>B,</b> Tumoral <i>CD8A</i> <i>CD8B</i> expression, RNA-seq. <b>C,</b> Percentage of cells CD3<sup>+</sup> baseline, FCM. <b>D,</b> Densities eTregs (Fr2)...
<p>Supplementary Figures and Tables.</p>
<div>Abstract<p>Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by cleavable linker, has been approved for patients HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response T-DXd. retrospective analysis included samples from treated T-DXd three clinical trials. We performed RNA sequencing multiplex IHC...
<p>Associations between pretreatment HER2 expression levels and therapy response to T-DXd. <b>A, </b><i>ERBB2</i> mRNA levels, as determined using RNA-seq. <b>B,</b> H-score, IHC. CPM, counts per million; CR, complete response; PD, progressive disease; PR, partial SD, stable disease.</p>
Abstract Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by cleavable linker, has been approved for patients HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response T-DXd. retrospective analysis included samples from treated T-DXd three clinical trials. We performed RNA sequencing multiplex IHC on archival tumor...